Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marwan Bukhari

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Rheumatology (Oxford, England)|August 24, 2018
The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritisChristopher R Holroyd, Rakhi Seth, Marwan Bukhari, et al.
Current Medical Research and Opinion|June 18, 2025
Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: final analysis from a prospective observational cohort study (ENDEAVOUR)James Taylor, Srinivasan Srirangan, Marwan Bukhari, et al.
Rheumatology (Oxford, England)|January 24, 2023
Quality standards for the care of people with giant cell arteritis in secondary careFiona L Coath, Marwan Bukhari, Georgina Ducker, et al.
Rheumatology (Oxford, England)|August 26, 2025
Coming to a hard stop? Effect of tapered tocilizumab after weekly tocilizumab cessation for giant cell arteritis: a multicentre evaluationVanessa Quick, Stephen Sah, Shirish Dubey, et al.
Rheumatology (Oxford, England)|November 12, 2023
Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in EnglandVanessa Quick, Mahdi Abusalameh, Sajeel Ahmed, et al.
Rheumatology Advances in Practice|October 15, 2025
Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scopeStephanie F Ling, Joshua L Bennett, Vanessa J Reid, et al.
Rheumatology (Oxford, England)|January 24, 2020
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritisSarah L Mackie, Christian Dejaco, Simone Appenzeller, et al.
Rheumatology (Oxford, England)|January 24, 2020
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summarySarah L Mackie, Christian Dejaco, Simone Appenzeller, et al.
The Lancet. Rheumatology|May 11, 2024
Risk loci involved in giant cell arteritis susceptibility: a genome-wide association studyGonzalo Borrego-Yaniz, Lourdes Ortiz-Fernández, Adela Madrid-Paredes, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Rheumatology (Oxford, England)|August 24, 2018
The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritisChristopher R Holroyd, Rakhi Seth, Marwan Bukhari, et al.
Current Medical Research and Opinion|June 18, 2025
Real-world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: final analysis from a prospective observational cohort study (ENDEAVOUR)James Taylor, Srinivasan Srirangan, Marwan Bukhari, et al.
Rheumatology (Oxford, England)|January 24, 2023
Quality standards for the care of people with giant cell arteritis in secondary careFiona L Coath, Marwan Bukhari, Georgina Ducker, et al.
Rheumatology (Oxford, England)|August 26, 2025
Coming to a hard stop? Effect of tapered tocilizumab after weekly tocilizumab cessation for giant cell arteritis: a multicentre evaluationVanessa Quick, Stephen Sah, Shirish Dubey, et al.
Rheumatology (Oxford, England)|November 12, 2023
Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in EnglandVanessa Quick, Mahdi Abusalameh, Sajeel Ahmed, et al.
Rheumatology Advances in Practice|October 15, 2025
Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scopeStephanie F Ling, Joshua L Bennett, Vanessa J Reid, et al.
Rheumatology (Oxford, England)|January 24, 2020
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritisSarah L Mackie, Christian Dejaco, Simone Appenzeller, et al.
Rheumatology (Oxford, England)|January 24, 2020
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summarySarah L Mackie, Christian Dejaco, Simone Appenzeller, et al.
The Lancet. Rheumatology|May 11, 2024
Risk loci involved in giant cell arteritis susceptibility: a genome-wide association studyGonzalo Borrego-Yaniz, Lourdes Ortiz-Fernández, Adela Madrid-Paredes, et al.
Pageof 8